
Spinogenix Secures WHO Approval for Codabakalner as SPG601 Name
The World Health Organization has officially designated the investigational therapy SPG601 as codabakalner, a key regulatory milestone for the first-in-class drug. Developed by Los Angeles-based Spinogenix, the oral treatment is currently entering Phase 2b/3 testing as a potential breakthrough for Fragile X syndrome, the leading inherited cause of intellectual disability.


























